PeptideSearch

GHRP-2

Tested in people

Get notified when the evidence changes.

It has been tested in people, but it is not an approved medicine. The studies are usually small.

Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-05-14

Also called Pralmorelin / KP-102 / Growth Hormone Releasing Peptide 2

Triggers a burst of growth hormone. Approved in Japan as a diagnostic test, not as a treatment.

Official status: 503A Category 3 – nominated without adequate support · Checked 2026-05-14

Can a doctor prescribe this?

Small pharmacy (503A)
Category 3 — not enough evidence sent in
Large outsourcing facility (503B)
Category 1 — under review, allowed for nowall routes except injection and nasal use

FDA entry: “GHRP-2 (except for injectable and nasal routes of administration)” · document dated 2025-03-21

Category 2 — FDA flagged a safety concerninjection and nasal use only

FDA entry: “GHRP-2 (for injectable and nasal routes of administration)” · document dated 2025-03-21

The FDA has "GHRP-2" in Category 3 of the substances put forward for small-pharmacy (503A) compounding: someone did put it forward, but what was sent in did not include enough evidence for the FDA to judge it. The separate list for large outsourcing facilities (503B) splits it by route, and that split is recorded on the timeline rather than as one flat category.

503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.

About the 503B list: FDA states it does not intend to place bulk drug substances nominated on or after 7 January 2025 into these categories. The category document is therefore not updated for new nominations — an older document date reflects a frozen process, not a lapsed one.

Lab suppliers we list: 7

Doses used in research

Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.

Spot an error? corrections@peptidesearch.org

What has happened so far

  1. 14 May 2026503A

    FDA lists "GHRP-2" under 503A Category 3: Bulk Drug Substances Nominated Without Adequate Support. Read from the FDA 503A category document headed "Updated May 14, 2026".

    FDA

  2. 21 March 2025503B

    The same 503B list places GHRP-2 in Category 2 "for injectable and nasal routes of administration". Category 2 is the list of substances raising significant safety risks. In plain terms: an outsourcing facility may not use GHRP-2 for injection or nasal use. Read from the FDA 503B bulk drug substances category list, document dated March 21, 2025 - seventeen months old at the time of this entry.

    FDA

  3. 21 March 2025503B

    The 503B list places GHRP-2 in Category 1 "except for injectable and nasal routes of administration". Category 1 means FDA does not intend to take action against its use in compounding while the nomination is under evaluation. In plain terms: an outsourcing facility may use GHRP-2 for non-injectable, non-nasal preparations. Read from the FDA 503B bulk drug substances category list, document dated March 21, 2025 - seventeen months old at the time of this entry.

    FDA

We'll email you when a new study, trial or status change lands for GHRP-2. Unsubscribe in one click.